Press Release May 12 2026
Filed with NSE · · 1 page · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallDr. Reddy's Laboratories Ltd. on 6ix
In the deck
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
- Press Release Apr 24 2026
- Press Release Mar 21 2026
- Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
- Press Release Feb 18 2026
Later from Dr. Reddy's Laboratories
- Press Release May 16 2026
- Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
- Press Release May 28 2026
- Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
- Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories